BGM Group Ltd. is a Cayman Islands holding company that operates as a pharmaceutical and chemical company through its subsidiaries and variable interest entity in China. It specializes in manufacturing and distributing active pharmaceutical ingredients, traditional Chinese medicine derivatives, and related products for animal husbandry, human health, and agricultural applications. Key offerings include oxytetracycline products such as tablets and APIs used in treating diseases in livestock and humans; licorice-based medicines and extracts for pharmaceutical formulations; heparin sodium preparations for cardiovascular and hemodialysis treatments; antibacterial pastes for skin conditions; sausage casings; and organic fertilizers to enhance crop yields and soil quality. The company also focuses on AI applications, intelligent robots, algorithmic computing, cloud computing, and biopharmaceuticals, particularly through platforms like DuXiaoBao for insurance sales, underwriting, claims processing, and customer service in the insurance sector. BGM Group Ltd. integrates AI-driven solutions across its operations to optimize pharmaceutical manufacturing and supply chains. Founded in 2019 and based in Chengdu, China, it serves global markets in healthcare, technology, and agriculture.